Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Role and Prognosis

Area of Science:

• Oncology
• Immunology
• Pathology

Background:

• Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma (NHL), with a significant portion of patients resistant to standard therapies.
• The tumor microenvironment's (TME) role in DLBCL pathogenesis and patient survival is less understood compared to other cancers.
• Identifying novel prognostic biomarkers and therapeutic targets is crucial due to treatment resistance in DLBCL.

Purpose of the Study:

• To review and highlight the influence of TME components on lymphoid clone progression in DLBCL.
• To explore the prognostic impact of TME interactions on DLBCL patient survival.
• To underscore the importance of TME investigation for understanding DLBCL.

Main Methods:

• Literature review focusing on studies investigating TME composition and its interaction with neoplastic cells in DLBCL.
• Analysis of research on specific genes (e.g., beta2-microglobulin, CD58), immune checkpoints (PD-1/PD-L1), and cellular components (Treg, TAM).
• Examination of the role of gene expression profiles, protein expression (SPARC, fibronectin), and matrix-modulating enzymes (MMPs, TIMPs) within the DLBCL microenvironment.

Main Results:

• TME composition and interactions influence DLBCL immune evasion, potentially explaining the roles of genes like beta2-microglobulin and CD58.
• Immune components such as PD-1, PD-L1, and Tregs are implicated in tumor progression and immune surveillance evasion.
• Factors like TAM phenotype, SPARC, fibronectin, MMPs, and TIMPs expression correlate with patient outcomes in DLBCL.

Conclusions:

• The TME plays a critical role in DLBCL pathogenesis and progression.
• Specific TME components and their interactions serve as potential prognostic biomarkers for DLBCL patients.
• Further research into the DLBCL TME is warranted for developing targeted therapies and improving patient survival.